Bortezomib-based chemotherapy in mantle cell lymphoma
- PMID: 30348536
- DOI: 10.1016/S1470-2045(18)30743-5
Bortezomib-based chemotherapy in mantle cell lymphoma
Comment on
-
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Similar articles
-
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.Leuk Lymphoma. 2018 Apr;59(4):896-903. doi: 10.1080/10428194.2017.1365855. Epub 2018 Jan 17. Leuk Lymphoma. 2018. PMID: 29338540 Clinical Trial.
-
Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):9-11. Clin Adv Hematol Oncol. 2014. PMID: 25768994 No abstract available.
-
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. N Engl J Med. 2015. PMID: 25738670 Clinical Trial.
-
Current treatment approaches for mantle-cell lymphoma.J Clin Oncol. 2005 Sep 10;23(26):6409-14. doi: 10.1200/JCO.2005.55.017. J Clin Oncol. 2005. PMID: 16155027 Review.
-
Mantle cell lymphoma: advances in biology and therapy.Curr Opin Hematol. 2008 Jul;15(4):415-21. doi: 10.1097/MOH.0b013e328302c9c5. Curr Opin Hematol. 2008. PMID: 18536582 Review.
Cited by
-
Computed tomography-based conventional imaging features and texture analysis characteristics of chemotherapy drug-related acute pancreatitis.Front Med (Lausanne). 2025 May 12;12:1497944. doi: 10.3389/fmed.2025.1497944. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40421297 Free PMC article.
-
Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.PLoS Pathog. 2020 Feb 24;16(2):e1008105. doi: 10.1371/journal.ppat.1008105. eCollection 2020 Feb. PLoS Pathog. 2020. PMID: 32092124 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources